(0.16%) 5 222.68 points
(0.32%) 39 513 points
(-0.03%) 16 341 points
(-1.34%) $78.20
(-2.13%) $2.25
(1.14%) $2 366.90
(0.11%) $28.40
(1.48%) $1 005.50
(0.11%) $0.928
(-0.30%) $10.83
(-0.01%) $0.798
(-0.42%) $92.15
2 days till quarter result
(amc 2024-05-13)
Expected move: +/- 0.00%
@ $7.58
Issued: 14 Feb 2024 @ 10:18
Return: -38.26%
Previous signal: Feb 13 - 12:30
Previous signal:
Return: -1.69 %
Live Chart Being Loaded With Signals
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines...
Stats | |
---|---|
Today's Volume | 869 998 |
Average Volume | 1.25M |
Market Cap | 455.55M |
EPS | $0 ( 2024-03-26 ) |
Next earnings date | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.920 |
ATR14 | $0.0100 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-09 | Lin Shao-lee | Buy | 964 829 | Employee Stock Option (right to buy) |
2024-01-09 | Lin Shao-lee | Buy | 413 498 | Employee Stock Option (right to buy) |
2024-01-09 | Labrucherie Gil M | Buy | 855 513 | Employee Stock Option (right to buy) |
2024-01-02 | Lin Shao-lee | Sell | 10 691 | Common Stock |
2023-12-18 | Tetrault Lynn A. | Buy | 89 955 | Director Stock Option (right to buy) |
INSIDER POWER |
---|
-1.31 |
Last 57 transactions |
Buy: 28 627 675 | Sell: 30 925 812 |
Volume Correlation
Acelyrin, Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Acelyrin, Inc. Correlation - Currency/Commodity
Acelyrin, Inc. Financials
Annual | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-12.25 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-12.25 |
Financial Reports:
No articles found.
Acelyrin, Inc.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators